Marketizing Protective Embryo Edits

If arguments like the MAHA case prevail, protective and enhancement embryo edits will shift from speculative science into a paid marketplace where clinics, third‑party analytics, and wealth determine who receives genetic resilience. That transition would produce rapid concentration of biologically conferred advantages unless regulated. — This reframes genome‑editing debate from abstract ethics to an imminent distributional policy problem — who gets resilient genomes, and how do we prevent a new hereditary elite?